What is the recommended treatment for allergic conjunctivitis?

Treatment of Allergic Conjunctivitis

For acute allergic conjunctivitis, start with topical dual-action agents (antihistamine plus mast cell stabilizer) such as olopatadine, ketotifen, or epinastine, as these provide rapid symptom relief within 30 minutes and are suitable for both acute and chronic treatment. 1

Initial Management Approach

Non-Pharmacological Measures

• Cold compresses and refrigerated artificial tears provide immediate symptomatic relief and help dilute allergens on the ocular surface 1
• Allergen avoidance strategies including wearing sunglasses as a barrier, hypoallergenic bedding, eyelid cleansers to remove allergens, and showering before bedtime 1
• Avoid eye rubbing, which can worsen symptoms and is associated with keratoconus progression 1

First-Line Pharmacological Treatment

Topical dual-action agents are superior to other topical medications because they combine antihistamine activity with mast cell stabilization, have rapid onset (within 30 minutes), and are effective for both acute flare-ups and chronic prophylaxis 1. Options include:

• Olopatadine (Pataday, Patanol) 1
• Ketotifen (Alaway, Zaditor) - available over-the-counter 1
• Epinastine (Elestat) 1
• Azelastine (Optivar) 1

Alternative First-Line Options

If dual-action agents are unavailable, consider:

• Topical antihistamines alone (emedastine, levocabastine) for acute symptom relief 1
• Combination antihistamine/vasoconstrictor (antazoline, pheniramine) works better than either agent alone for acute relief, but limit use to 10 days to avoid rebound hyperemia 1
• Mast cell stabilizers alone (cromolyn, lodoxamide, nedocromil) require several days for optimal effect and are better suited for prophylaxis in chronic cases 1

Second-Line Treatment for Inadequate Control

Short-Term Topical Corticosteroids

If symptoms are not adequately controlled with first-line agents, add a brief 1-2 week course of topical corticosteroids with a low side-effect profile 1. However, reserve corticosteroids for more severe symptoms due to vision-threatening complications including cataract formation, elevated intraocular pressure, and secondary infections 1.

• Loteprednol etabonate (Alrex) has a greatly reduced risk of causing increased IOP compared to other ocular corticosteroids 1
• Baseline and periodic IOP measurement and pupillary dilation are mandatory when using corticosteroids to monitor for glaucoma and cataract 1

Topical Immunomodulators

For severe cases or chronic disease requiring repeated corticosteroid courses, topical cyclosporine or tacrolimus should be considered 1:

• Cyclosporine 0.1% is FDA-approved for severe vernal conjunctivitis and has been shown effective when used at least four times daily 1
• Cyclosporine 0.05% (used off-label at higher frequency) reduces signs and symptoms and prevents seasonal recurrences 1
• These agents allow for reduced corticosteroid use 1

Systemic Therapy Considerations

Intranasal Corticosteroids

Intranasal corticosteroids (such as fluticasone furoate) significantly reduce ocular symptoms in patients with concomitant allergic rhinitis and are equally effective as oral or intranasal antihistamines for eye symptoms 1

Oral Antihistamines

Oral antihistamines are generally less effective than topical ophthalmic agents for ocular symptoms, have slower onset of action, and may worsen dry eye by causing excessive tear film drying 1. Use cautiously and consider concomitant preservative-free artificial tears 1

Allergen Immunotherapy

Allergen immunotherapy is recommended as a therapeutic option for patients with documented IgE-mediated disease who have inadequate response to pharmacotherapy 1

Critical Pitfalls to Avoid

• Do not use vasoconstrictors alone (naphazoline, tetrahydrozoline) as they only relieve redness without addressing the allergic response 1
• Limit vasoconstrictor use to 10 days maximum to prevent rebound hyperemia and conjunctivitis medicamentosa 1
• Never use corticosteroids without monitoring IOP and lens status, as vision-threatening complications can develop 1
• Recognize that topical NSAIDs (ketorolac) provide only temporary relief of itching and are less effective than dual-action agents 1

Follow-Up Strategy

Frequency of follow-up depends on disease severity and treatment used 1:

• Patients on topical corticosteroids require baseline and periodic IOP checks and dilated exams 1
• Timing visits during symptomatic periods helps assess treatment efficacy 1
• All follow-up visits should include visual acuity measurement and slit-lamp biomicroscopy 1